<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00869284</url>
  </required_header>
  <id_info>
    <org_study_id>GOELAMS 073</org_study_id>
    <secondary_id>no other identification number</secondary_id>
    <nct_id>NCT00869284</nct_id>
  </id_info>
  <brief_title>Long-Term Follow-up of Tandem High-Dose Therapy With Peripheral Blood Stem Cell for Adults With High-Risk Age-Adjusted IPI Aggressive Non-Hodgkin's Lymphomas</brief_title>
  <acronym>073</acronym>
  <official_title>Phase II Study Treatment of High Risk Non-Hodgkin's Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French Innovative Leukemia Organisation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>French Innovative Leukemia Organisation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II multicenter pilot trial (073) evaluating tandem HDT with PBSC support in aa-IPI=3
      untreated aggressive NHL.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      High-dose chemotherapy; untreated aggressive non-Hodgkin's lymphoma; high-risk; peripheral
      blood stem cell support Patients were aged from 15 to 60 years
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 1994</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">July 1999</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete response</measure>
    <time_frame>end of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival disease free survival</measure>
    <time_frame>10 years after treatment</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">45</enrollment>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CEEP regimen</intervention_name>
    <description>cyclophosphamide 1200 mg/m² intravenously on day 1 (d1), epirubicin 100 mg/m² intravenously on d1, vindesine 3 mg/m² intravenously on d1 and prednisone 80 mg/m² orally or intravenously on d1-5, with two weeks intervals</description>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Tandem high-dose therapy (HDT) followed by autologous peripheral blood stem cell (PBSC)</intervention_name>
    <description>The conditioning regimen of the first HDT was mitoxantrone 45 mg/m² intravenously on d1 + cytarabine 1000 mg/m² by a 3-hour infusion every 12 hours from d1-4.
The conditioning regimen of the second HDT started d30 to d45 after the first stem cell infusion, and consisted of 1200 cGy total body irradiation (TBI) in 6 twice daily 200 cGy fractionated doses with a 800 cGy pulmonary shielding, followed by CBV: carmustine 300 mg/m² intravenously on d4, etoposide 200 mg/m² intravenously on d5-8 and cyclophosphamide 1500 mg/m² intravenously on d5-8.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients aged from 15 to 60 years

          -  previously untreated

          -  histologically proven aggressive NHL

          -  high aa-IPI (equal to 3)

          -  proper underlying organ function

        Exclusion Criteria:

          -  transformed low-grade, lymphoblastic, mantle-cell, or Burkitt's lymphoma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Noël MILPIED, MDPD</last_name>
    <role>Principal Investigator</role>
    <affiliation>French Innovative Leukemia Organisation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emmanuel Gyan</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2009</study_first_submitted>
  <study_first_submitted_qc>March 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2009</study_first_posted>
  <last_update_submitted>March 24, 2009</last_update_submitted>
  <last_update_submitted_qc>March 24, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2009</last_update_posted>
  <responsible_party>
    <name_title>Pr Noel MILPIED</name_title>
    <organization>Groupe Ouest Est des Leucémies et autres maladies du sang</organization>
  </responsible_party>
  <keyword>High-dose chemotherapy</keyword>
  <keyword>aggressive NHL</keyword>
  <keyword>high-risk</keyword>
  <keyword>PBSC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

